# Elsunersen PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/elsunersen

> The next catalyst for elsunersen, sponsored by Praxis Precision Medicines, Inc. (PRAX), is its topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, quarter only, month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for elsunersen?

The next catalyst for elsunersen, sponsored by Praxis Precision Medicines, Inc. (PRAX), is its topline data readout, 2027. SEC Form 10-K: "We have initiated EMBRAVE3, a Phase 3 registrational study evaluating the efficacy, safety, tolerability and PK of elsunersen in early-onset SCN2A-DEE, and expect to announce topline results in 2027." [Calendar and source filings](https://sec-api.dev/pdufa/elsunersen)

Source: SEC Form 10-K, accession 0001689548-26-000029, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/elsunersen#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | elsunersen |
| Codes | PRAX-222 |
| Sponsor | Praxis Precision Medicines, Inc. (PRAX) https://sec-api.dev/companies/prax/catalysts |
| Indications |  |
| Modality | antisense |
| FDA designations | breakthrough |

## Timeline

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-29, last confirmed 2025-05-02.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000021): "With regulatory feedback on the elsunersen program, we expect to initiate the pivotal trial in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "The EMBRAVE study with elsunersen is progressing very well, with topline results expected in the first half of next year to support the registrational package, and we will initiate the Phase 3 EMBRAVE3 trial for elsunersen by mid-2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm
- SEC Form 10-K (accession 0001689548-25-000040): "We are continuing to evaluate elsunersen in the second cohort of the EMBRAVE study in Brazil, and plan to initiate EMBRAVE3, a Phase 3 registrational study, by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-05-02, last confirmed 2025-05-02.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "While the interim analysis of Essential3 study 1 for ulixacaltamide was not what we expected, we are on track to complete both study 1 and study 2 for topline readout in the third quarter of this year." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2025-02-28, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000037): "oThe second cohort of the EMBRAVE study evaluating safety and efficacy of elsunersen versus sham procedure continues enrolling patients in Brazil, with topline readout anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm
- SEC Form 10-K (accession 0001689548-26-000029): "For our most advanced product candidate under the Solidus™ platform, elsunersen, we expect to announce topline results for the EMBRAVE Part A study evaluating the safety and efficacy of elsunersen versus sham procedure in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- SEC Form 10-K (accession 0001689548-25-000040): "We are enrolling patients in the second cohort of the EMBRAVE study in Brazil, in which we are evaluating the safety and efficacy of elsunersen versus sham-procedure, and anticipate topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm
- SEC Form 8-K (accession 0001689548-25-000116): "The Company expects to complete Part A and disclose the topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm
- SEC Form 10-K (accession 0001689548-26-000029): "We expect to disclose the topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000028): "oThe EMBRAVE Part A Phase 1/2 study evaluating SCN2A early seizure onset patients with a 3:1 drug to sham arm evaluating safety and seizure reduction is on track for topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000110): "•The EMBRAVE Part A Phase 1/2 study is on track for topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "The EMBRAVE study with elsunersen is progressing very well, with topline results expected in the first half of next year to support the registrational package, and we will initiate the Phase 3 EMBRAVE3 trial for elsunersen by mid-2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm

### Apr 2026: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2026-05-07, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001689548-26-000089): "For our most advanced product candidate under the Solidus™ platform, elsunersen, we announced positive topline results in April 2026 from the EMBRAVE Part A study evaluating the safety and efficacy of elsunersen versus sham procedure for treating SCN2A gain-of-function DEE." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "For our most advanced product candidate under the Solidus™ platform, elsunersen, we announced positive topline results in April 2026 from the EMBRAVE Part A study evaluating the safety and efficacy of elsunersen versus sham procedure for treating SCN2A gain-of-function DEE." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "For our most advanced product candidate under the Solidus™ platform, elsunersen, we announced positive topline results from the EMBRAVE Part A study evaluating the safety and efficacy of elsunersen versus sham procedure in April 2026 for treating SCN2A gain-of-function DEE." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-02-19, last confirmed 2026-11-09.
- SEC Form 10-K (accession 0001689548-26-000029): "We have initiated EMBRAVE3, a Phase 3 registrational study evaluating the efficacy, safety, tolerability and PK of elsunersen in early-onset SCN2A-DEE, and expect to announce topline results in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- SEC Form 10-Q (accession 0001689548-26-000089): "We are currently enrolling EMBRAVE3, a Phase 3 registrational study for early-seizure-onset SCN2A DEE, and expect to announce topline results in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "We are currently enrolling EMBRAVE3, a Phase 3 registrational study for early-seizure-onset SCN2A DEE, and expect to announce topline results in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "We are currently enrolling EMBRAVE3, a Phase 3 registrational study for SCN2A gain-of-function DEE, and expect to announce topline results in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- SEC Form 10-K (accession 0001689548-26-000029): "We are currently enrolling EMBRAVE3, a Phase 3 registrational study for SCN2A gain-of-function DEE, and expect to announce topline results in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "•Enrollment in the EMBRAVE3 registrational trial is progressing, with topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "oEnrollment is progressing in the EMBRAVE3 registrational trial, with topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/elsunersen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Elsunersen PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/elsunersen

```bibtex
@misc{secapidev_pdufa_elsunersen_20261116,
  title        = {Elsunersen PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/elsunersen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_elsunersen_20261116","title":"Elsunersen PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/elsunersen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
